Alexion Pharma (ALXN) Gains Amid Conference Call
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
Alexion Pharma (NASDAQ: ALXN) gained on statements made during its conference call.
It sees Q1 product revenue of $585-$590. 2015 tax rate is seen at 7%-9% vs 13%-15% prior. It expected US and EU decisions on Asfotase Alfa by mid-year, and Japan by the end of the year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla (TSLA) Delivered 486,532 Vehicles in Q3 vs Consensus of 461,974
- Integra LifeSciences cuts 2026 outlook after Cincinnati flood
- Gen Digital CEO addresses acquisition rumors and raises fiscal 2027 outlook
Create E-mail Alert Related Categories
Guidance, Management Comments, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
